Ruxience

BIOLOGICAL2 trials

Sponsors

National Cancer Institute (NCI), Merck Sharp & Dohme LLC

Conditions

Chronic Lymphocytic LeukemiaHairy Cell LeukemiaSmall Lymphocytic Lymphoma

Phase 1

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Active, not recruitingNCT03805932

National Cancer Institute (NCI)Hairy Cell Leukemia

Start: 2019-10-03End: 2029-06-30Updated: 2026-06-29

Phase 3

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Active, not recruitingNCT05624554

Merck Sharp & Dohme LLCChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Start: 2023-03-16End: 2031-03-17Target: 300Updated: 2026-03-16

Related Papers

Effect of rituximab on remissions without minimal residual disease and immunogenicity in patients with relapsed/refractory hairy cell leukemia receiving moxetumomab pasudotox.

Journal of Clinical Oncology2024-06-011 citations

Abstract B170: The <i>in vitro</i> anti-tumor activity of the multi-kinase inhibitor nemtabrutinib (ARQ-531, MK-1026) is seen across multiple B-cell lymphoma subtypes, only partially overlapping with what achieved by single BTK inhibition

Molecular Cancer Therapeutics2023-12-01

EFFICACY AND SAFETY OF NEMTABRUTINIB VERSUS CHEMOIMMUNOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITHOUT TUMOR PROTEIN 53 ABERRATIONS: THE OPEN-LABEL, RANDOMIZED, PHASE 3 BELLWAVE-008 STUDY

Hematology Transfusion and Cell Therapy2023-10-01

BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.

Journal of Clinical Oncology2023-06-01

Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.

Journal of Clinical Oncology2021-05-20